Methods
platinum-sensitive, primary peritoneal carcinoma
PRIMARY PERITONEAL CARCINOMA, DISEASE, EPITHELIAL OVARIAN CARCINOMA, FALLOPIAN TUBE CANCER
Parallel multicenter, single-arm, phase II studies using a Simon two-stage design. Eligible patients had a histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma and demonstration of platinum-sensitive (≥6 months [mo]) or -resistant disease (relapse 2-6 mo post-platinum). Carboplatin (AUC 4 IV day 1), gemcitabine (1000 mg/m